Evidence map›Paper›PMID 42283395›Full record

ArticleGenes, chromosomes & cancer2026

Cytogenetic and Molecular Analysis of a "Double-Hit" RUNX1 Including a RUNX1 p.Trp279* and a Cryptic Novel t(6;21)(q25;q22)/RUNX1::ARID1B in Acute Myeloid Leukemia.

Rolando García, Jing Xu, Lan Yu, Kalayarasan Srinivasan, Sharon Koorse Germans, Olga Weinberg, Franklin Fuda, Weina Chen, Prasad Koduru

Abstract read
In one paragraph

Article in Genes, chromosomes & cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rolando GarcíaDepartment of Pathology, UT Southwestern Medical Center, Dallas, Texas, USA.
Jing XuDepartment of Pathology, UT Southwestern Medical Center, Dallas, Texas, USA.
Lan YuDepartment of Pathology, UT Southwestern Medical Center, Dallas, Texas, USA.
Kalayarasan SrinivasanDepartment of Pathology, UT Southwestern Medical Center, Dallas, Texas, USA.
Sharon Koorse GermansDepartment of Pathology, UT Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0001-9275-6056
Olga WeinbergDepartment of Pathology, UT Southwestern Medical Center, Dallas, Texas, USA.
Franklin FudaDepartment of Pathology, UT Southwestern Medical Center, Dallas, Texas, USA.
Weina ChenDepartment of Pathology, UT Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0001-5638-4371
Prasad KoduruDepartment of Pathology, UT Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0001-7109-5906

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAlterations involving RUNX1 are recurrent in hematologic malignancies and contribute to disease pathogenesis via dysregulation of transcriptional factors essential for hematopoiesis. Here, we report an acquired alteration in both alleles of RUNX1; one is a truncating mutation and the second is a novel RUNX1::ARID1B identified in acute myeloid leukemia.

methodsBone marrow samples were assessed by morphologic examination and flow cytometry. Cytogenetic analysis was performed using conventional G-banded karyotyping and fluorescence in situ hybridization (FISH). Molecular profiling was performed using next-generation sequencing (NGS) for single nucleotide changes, copy number variations, gene fusions, and expression.

resultsMorphology showed large-sized myeloblasts that are CD34+ and CD45+ (dim) consistent with acute myeloid leukemia. Genetic analysis of diagnostic specimen showed normal karyotype and FISH results but detected mutations in IDH1 and RUNX1. Cytogenetic analysis of a specimen at relapse showed complex abnormal karyotype and FISH detected RUNX1 rearrangement with 6q25. NGS identified this rearrangement as RUNX1::ARID1B. Thus, at this stage leukemia cells had "double-hit" abnormality in RUNX1. Gene transcript evaluation showed elevated levels of transcripts of both RUNX1 and ARIDB1.

conclusionThis study expands the spectrum of RUNX1 fusions and highlights the integral diagnostic value of morphology, flow cytometry, cytogenetics, FISH, and NGS analyses for broad structural variant detection in clinical practice. Furthermore, the truncating mutation in one allele of RUNX1 and RUNX1::ARID1B of the second allele detected with advanced disease suggests the possibility of combined transcriptional and chromatin regulatory alterations in disease recurrence in the patient.

Indexed as

Core Binding Factor Alpha 2 SubunitDNA-Binding ProteinsLeukemia, Myeloid, AcuteTranscription FactorsTranslocation, GeneticChromosomes, Human, Pair 21Chromosomes, Human, Pair 6FemaleHumansIn Situ Hybridization, FluorescenceMaleMutationCore Binding Factor Alpha 2 SubunitDNA-Binding ProteinsRUNX1 protein, humanTranscription Factors

Identifiers

PMID42283395
PMCPMC13262018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.